Show simple item record

dc.contributor.authorMartínez-Esteban, P.C.
dc.contributor.authorGuillén-Pinto, D.
dc.contributor.authorDuran Padrós, A.A.
dc.contributor.authorKoc-Gonzales, D.
dc.contributor.authorFlores-Bravo, J.
dc.contributor.authorMéndez-Dávalos, C.
dc.contributor.authorSuyo-Suyo-Suyo, C.
dc.contributor.authorEspíritu-Rojas, E.R.
dc.contributor.authorCaballero-Bedón, N.
dc.contributor.authorCelis-García, L.E.
dc.contributor.authorChávez-Pasco, V.G.
dc.contributor.authorGranados-Guibovich, K.
dc.contributor.authorGraña-Espinoza, J.M.
dc.contributor.authorAlva-Diaz, C.
dc.date.accessioned2025-10-31T18:32:58Z
dc.date.available2025-10-31T18:32:58Z
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/20.500.12805/4829
dc.description.abstractObjective: to provide evidence-based clinical recommendations for the diagnosis and treatment of Duchenne Muscular Dystrophy. Methods: a guideline development group (GEG) was formed that included specialized physicians in the fields of neurology, neuropediatrics, genetics, and methodology. The GEG asked eight clinical questions to be answered by recommendations in this clinical practice guidelines (CPG). We conducted a systematic search and - when deemed relevant - primary studies in Medline, Scopus, and the Cochrane Controlled Register of Trials during 2021 were reviewed. Evidence was selected to answer each of the clinical questions posed. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. In periodic work meetings, the GEG used the GRADE methodology to review the evidence and formulate recommendations, points of good clinical practice, and a diagnosis and treatment flowchart. Results: this CPG addressed eight clinical questions, divided into three topics: screening, diagnosis, and treatment. Based on these questions, fifteen recommendations were formulated (10 strong, 5 conditional) and 11 points for good clinical practice. Conclusion: this paper summarizes the methodology and evidence-based conclusions of the CPG for the diagnosis and treatment of Duchenne muscular dystrophy.en_US
dc.formatapplication/pdf
dc.language.isospa
dc.publisherColegio Médico del Perú
dc.relation.ispartofurn:issn:1728-5917
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectMuscle Regeneration and Dystrophy Mechanismsen_US
dc.subjectDuchenne Muscular Dystrophy: Advances in Patient Careen_US
dc.titleGuía de práctica clínica para el diagnóstico y tratamiento de la distrofia muscular de Duchenne. Sociedad Peruana de Neurología. Versión Cortaes_PE
dc.title.alternativeClinical Practice Guidelines for diagnosis and treatment of Duchenne muscular dystrophy. Peruvian Neurology Society. Short Versionen_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.doihttps://doi.org/10.35663/amp.2022.392.2376
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.25
dc.type.otherResearch article
dc.identifier.journalActa Medica Peruana
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2